DNA vaccines against leptospirosis: A literature review

Silveira, Marcelle Moura; Oliveira, Thaís Larré; Schuch, Rodrigo Andrade; McBride, Alan J. A.; Dellagostin, Odir A.; Hartwig, Daiane Drawanz

doi:10.1016/j.vaccine.2017.08.067

Cited by 54 publications

(62 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The immunity of Leptospira is serovar-specific and there are so many types of serovars present worldwide therefore multivalent bacterin formulations having locally prevalent serovar are used for immunization of cattle, pigs, and dogs worldwide (Bolin et al, 1991). Some recombinant vaccines based on outer membrane proteins, leptospira immunoglobuline-like proteins, and lipoproteins of leptospira were also experimentally evaluated but none of them are available for immunization purpose (Silveira et al, 2017;Faine et al, 1999;Levett, 2001).…”

Section: Leptospirosismentioning

confidence: 99%

Vaccines the tugboat for prevention-based animal production

Nimmanapalli

Gupta

2020

Genomics and Biotechnological Advances in Veterinary, Poultry, and Fisheries

View full text Add to dashboard Cite

Section: Leptospirosismentioning

confidence: 99%

Vaccines the tugboat for prevention-based animal production

Nimmanapalli

Gupta

2020

Genomics and Biotechnological Advances in Veterinary, Poultry, and Fisheries

View full text Add to dashboard Cite

“…These vaccines have been shown to elicit a robust cytotoxic T cell in comparison with subunit vaccines. Also, DNA vaccine has the capacity to induce both cellular and humoral immune responses by utilizing MHC I and MHC II antigen presentation by DCs [1][2][3]. Although DNA vaccines are licensed for use in veterinary vaccines since 2005, they have their own limitation due to low transfection efficiency.…”

Section: Dna Vaccinementioning

confidence: 99%

“…Although DNA vaccines are licensed for use in veterinary vaccines since 2005, they have their own limitation due to low transfection efficiency. As a result, they perform poorly in human clinical trials and require multiple booster doses to achieve desirable immune response [2,4,5]. With the advent of new adjuvant systems such as nanoparticles, the immunogenicity of DNA vaccines can be enhanced considerably [1].…”

Section: Dna Vaccinementioning

confidence: 99%

Current State of the Art in DNA Vaccine Delivery and Molecular Adjuvants: Bcl-xL Anti-Apoptotic Protein as a Molecular Adjuvant

Gülce-İz¹,

Sağlam-Metiner²

2019

Immune Response Activation and Immunomodulation

View full text Add to dashboard Cite

DNA vaccines (nucleic acid vaccines) have been gaining importance as promising therapeutics against infectious diseases, cancer, autoimmune disorders and allergy for the past two decades. However, the immune responses elicited by the DNA vaccines are not at the desired level to stimulate a protective immune response. Thus, studies are focused on the enhancement of DNA vaccine-induced immune response by different approaches. The most common approach is to use biomaterial-based adjuvants for enhanced antigen delivery and uptake by antigenpresenting cells. Some of these adjuvants are alum, saponins, microspheres, nanoparticles, liposomes, polymers, etc. used in vaccine formulations. In addition, molecular adjuvants like cytokines, chemokines and heat shock proteins have been shown to be promising in designing DNA vaccines. In this chapter, molecular adjuvants to improve DNA vaccination-induced immune responses will be summarized with a special focus on Bcl-xL anti-apoptotic protein.

show abstract

“…NPs can induce a robust innate immunity response by causing abundant initial antigen exposure and long-term immunity through the sustained release of antigens via two types of activation modes: dendritic cell (DC) and T-cell differentiation. (12,13,14) In previous studies, we demonstrated that subunit vaccines containing recombinant proteins, LipL32 (10) and LigAni, (11) with halloysite nanotubes (HNTs) and carboxylated multi-walled carbon nanotubes (COOH-MWCNTs) as carriers induced a strong IgG immune response in Golden Syrian hamsters.…”

mentioning

confidence: 99%

“…(16,17,18) Over the last two decades, to increase the efficacy of vaccines against leptospirosis, several DNA vaccines have been formulated using novel strategies, such as the introduction of novel plasmid vectors, adjuvants, alternative delivery routes, and prime-boost regimens. (13) DNA vaccines are promising because they can trigger both humoral and cellular immune responses, thus providing long-term protective immunity. However, naked DNA can hardly enter into cells and is easily degraded by DNases and lysosomes, thus highlighting the need for assessing effective delivery systems.…”

mentioning

confidence: 99%

DNA nanovaccines prepared using LemA antigen protect Golden Syrian hamsters against Leptospira lethal infection

Oliveira

Bacelo

Forster

et al. 2020

Mem. Inst. Oswaldo Cruz

Self Cite

View full text Add to dashboard Cite

BACKGROUND Nanoparticles (NPs) are viable candidates as carriers of exogenous materials into cells via transfection and can be used in the DNA vaccination strategy against leptospirosis. OBJECTIVES We evaluated the efficiency of halloysite clay nanotubes (HNTs) and amine-functionalised multi-walled carbon nanotubes (NH 2-MWCNTs) in facilitating recombinant LemA antigen (rLemA) expression and protecting Golden Syrian hamsters (Mesocricetus auratus) against Leptospira interrogans lethal infection. METHODS An indirect immunofluorescent technique was used to investigate the potency of HNTs and NH 2-MWCNTs in enhancing the transfection and expression efficiency of the DNA vaccine in Chinese hamster ovary (CHO) cells. Hamsters were immunised with two doses of vaccines HNT-pTARGET/lemA, NH 2-MWCNTs-pTARGET/lemA, pTARGET/lemA, and empty pTARGET (control), and the efficacy was determined in terms of humoral immune response and protection against a lethal challenge. FINDINGS rLemA DNA vaccines carried by NPs were able to transfect CHO cells effectively, inducing IgG immune response in hamsters (p < 0.05), and did not exhibit cytotoxic effects. Furthermore, 83.3% of the hamsters immunised with NH 2-MWCNTs-pTARGET/lemA were protected against the lethal challenge (p < 0.01), and 66.7% of hamsters immunised with HNT-pTARGET/ lemA survived (p < 0.05). MAIN CONCLUSIONS NH 2-MWCNTs and HNTs can act as antigen carriers for mammalian cells and are suitable for DNA nanovaccine delivery.

show abstract

DNA vaccines against leptospirosis: A literature review

Cited by 54 publications

References 96 publications

Vaccines the tugboat for prevention-based animal production

Vaccines the tugboat for prevention-based animal production

Current State of the Art in DNA Vaccine Delivery and Molecular Adjuvants: Bcl-xL Anti-Apoptotic Protein as a Molecular Adjuvant

DNA nanovaccines prepared using LemA antigen protect Golden Syrian hamsters against Leptospira lethal infection

Contact Info

Product

Resources

About